Objects
Lizak, Nathaniel, Hodgkinson, Suzanne, Butler, Ernest, Lechner-Scott, Jeannette, Slee, Mark, McCombe, Pamela Ann, Shaw, Cameron, Skibina, Olga, Vucic, Steve, Shuey, Neil, Barnett, Michael H., Parratt, John, Butzkueven, Helmut, Jack, Dominic, Fabris, Jessica, Kalincik, Tomas. Sage; 2021. Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: an MSBase registry substudy.
Tao, Chunrong, Simpson, Steve, Duquette, Pierre, Girard, Marc, Grand'Maison, Francois, Grammond, Pierre, Alroughani, Raed, Terzi, Murat, Oreja-Guevara, Celia, Sajedi, Seyed Aidin, Iuliano, Gerardo, Sola, Patrizia, van der Mei, Ingrid, Lechner-Scott, Jeannette, Van Pesch, Vincent, Pucci, Eugenio, Bergamaschi, Roberto, Barnett, Michael, Ramo, Cristina, Singhal, Bhim, Spitaleri, Daniele L. A., Slee, Mark, Verheul, Freek, Blizzard, Leigh, Fernández Bolaños, Ricardo, Amato, Maria Pia, Cristiano, Edgardo, Granella, Franco, Hodgkinson, Suzanne, Fiol, Marcela, Gray, Orla, McCombe, Pamela, Saladino, Maria Laura, Sánchez Menoyo, José Luis, Havrdova, Eva, Shuey, Neil, Vucic, Steve, Shaw, Cameron, Deri, Norma, Arruda, Walter Oleschko, Butzkueven, Helmut, Spelman, Tim, Taylor, Bruce V., Horakova, Dana, Shaygannejad, Vahid, Lugaresi, Alessandra, Izquierdo, Guillermo, Trojano, Maria. BMJ Group; 2016. Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis.
Zhong, Michael, van der Walt, Anneke, Butler, Ernest, Prevost, Julie, Girard, Marc, Oh, Jiwon, Butzkueven, Helmut, Jokubaitis, Vilija, Monif, Mastura, Hodgkinson, Suzanne, Eichau, Sara, Kalincik, Tomas, Lechner-Scott, Jeannette, Buzzard, Katherine, Skibina, Olga, Van Pesch, Vincent. Sage Publications; 2023. Prediction of relapse activity when switching to cladribine for multiple sclerosis.
Jokubaitis, Vilija G., Li, Vivien, Barnett, Michael, Grand'Maison, Francois, Trojano, Maria, Slee, Mark, Giuliani, Giorgio, Shaw, Cameron, Boz, Cavit, Spitaleri, Daniele L. A., Verheul, Freek, Haartsen, Jodi, Kalincik, Tomas, Liew, Danny, Butzkueven, Helmut, Izquierdo, Guillermo, Hodgkinson, Suzanne, Alroughani, Raed, Lechner-Scott, Jeannette, Lugaresi, Alessandra, Duquette, Pierre, Girard, Marc. Lippincott Williams & Wilkins; 2014. Fingolimod after natalizumab and the risk of short-term relapse.
Broadley, Simon A., Barnett, Michael H., Marriott, Mark, Mason, Deborah F., Parratt, John, Reddel, Stephen W., Shaw, Cameron P., Slee, Mark, Spies, Judith, Taylor, Bruce V., Carroll, William M., Kilpatrick, Trevor J., Boggild, Mike, King, John, McCombe, Pamela A., Pollard, John D., Willoughby, Ernest, Brew, Bruce J., Butzkueven, Helmut, Heard, Robert, Hodgkinson, Suzanne, Kermode, Allan G., Lechner-Scott, Jeannette, Macdonell, Richard A. L.. Elsevier; 2014. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 2 New and emerging therapies and their efficacy.
Spelman, Tim, Ozakbas, Serkan, Soysal, Aysun, Kuhle, Jens, Sanchez-Menoyo, Jose Luis, Morgado, Yolanda Blanco, Spitaleri, Daniele L. A., Pesch, Vincent Van, Horakova, Dana, Ampapa, Radek, Patti, Francesco, Macdonell, Richard, Alroughani, Raed, Al-Asmi, Abdullah, Gerlach, O, Oh, J, Altintas, A, Tundia, N, Wong, SL, Butzkueven, H, MSBase Study Group,, Terzi, Murat, Hodgkinson, Suzanne, Laureys, Guy, Kalincik, Tomas, Der Walt, Anneke Van, Yamout, Bassem, Lechner-Scott, Jeannette. Future Medicine; 2023. A plain language summary on the effectiveness of cladribine tablets compared with other oral treatments for multiple sclerosis: results from the MSBase registry.
Chan, Andrew, Rose, John, Wright, Katy, Ferraro, Diana, Sola, Patrizia, Hodgkinson, Suzanne, Kalincik, Tomas, Lechner-Scott, Jeanette, McGuigan, Christopher, Spach, Karen, Chen, Chongshu, Fam, Sami, Alvarez, Enrique, Wu, Fan, Miller, Catherine, Bar-Or, Amit, Butzkueven, Helmut, Fox, Robert J., Gold, Ralf, Gudesblatt, Mark, Haartsen, Jodi, Spelman, Tim. Lippincott Williams & Wilkins; 2020. Lymphocyte reconstitution after DMF discontinuation in clinical trial and real-world patients with MS.
Broadley, Simon A., Barnett, Michael H., Marriott, Mark, Mason, Deborah F., Parratt, John, Reddel, Stephen W., Shaw, Cameron P., Slee, Mark, Spies, Judith, Taylor, Bruce V., Carroll, William M., Kilpatrick, Trevor J., Boggild, Mike, King, John, McCombe, Pamela A., Pollard, John D., Willoughby, Ernest, Brew, Bruce J., Butzkueven, Helmut, Heard, Robert, Hodgkinson, Suzanne, Kermode, Allan G., Lechner-Scott, Jeannette, Macdonell, Richard A. L.. Elsevier; 2014. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 1 Historical and established therapies.
Lorscheider, Johannes, Buzzard, Katherine, Jokubaitis, Vilija, Spelman, Tim, Horakova, Dana, Trojano, Maria, Izquierdo, Guillermo, Girard, Marc, Duquette, Pierre, Prat, Alexandre, Lugaresi, Alessandra, Grand'Maison, François, Grammond, Pierre, Hupperts, Raymond, Alroughani, Raed, Sola, Patrizia, Boz, Cavit, Pucci, Eugenio, Lechner-Scott, Jeanette, Bergamaschi, Roberto, Oreja-Guevara, Celia, Iuliano, Gerardo, Van Pesch, Vincent, Granella, Franco, Ramo-Tello, Cristina, Spitaleri, Daniele, Petersen, Thor, Slee, Mark, Verheul, Freek, Ampapa, Radek, Amato, Maria Pia, McCombe, Pamela, Vucic, Steve, Sánchez Menoyo, José Luis, Cristiano, Edgardo, Barnett, Michael H., Hodgkinson, Suzanne, Olascoaga, Javier, Laura Saladino, Maria, Havrdova, Eva, Gray, Orla, Shaw, Cameron, Moore, Fraser, Butzkueven, Helmut, Kalincik, Tomas. Oxford University Press; 2016. Defining secondary progressive multiple sclerosis.
Broadley, Simon A., Barnett, Michael H., Marriott, Mark, Mason, Deborah F., Parratt, John, Reddel, Stephen W., Shaw, Cameron P., Slee, Mark, Spies, Judith, Taylor, Bruce V., Carroll, William M., Kilpatrick, Trevor J., Boggild, Mike, King, John, McCombe, Pamela A., Pollard, John D., Willoughby, Ernest, Brew, Bruce J., Butzkueven, Helmut, Heard, Robert, Hodgkinson, Suzanne, Kermode, Allan G., Lechner-Scott, Jeannette, Macdonell, Richard A. L.. Elsevier; 2014. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: An Australian and New Zealand perspective Part 3 Treatment practicalities and recommendations.
Broadley, Simon A., Barnett, Michael H., Marriott, Mark, Mason, Deborah F., Parratt, John, Reddel, Stephen W., Shaw, Cameron P., Slee, Mark, Spies, Judith M., Taylor, Bruce V., Carroll, William M., Kilpatrick, Trevor J., Boggild, Mike, King, John, McCombe, Pamela A., Pollard, John D., Willoughby, Ernest, Brew, Bruce J., Butzkueven, Helmut, Heard, Robert, Hodgkinson, Suzanne, Kermode, Allan G., Lechner-Scott, Jeannette, Macdonell, Richard A. L.. Australasian Medical Publishing Company Pty. Ltd.; 2015. A new era in the treatment of multiple sclerosis.
Spelman, Tim, Ozakbas, Serkan, Soysal, Aysun, Kuhle, Jens, Sanchez-Menoyo, Jose Luis, Blanco Morgado, Yolanda, Spitaleri, Daniele L. A., van Pesch, Vincent, Horakova, Dana, Ampapa, Radek, Patti, Francesco, Macdonell, Richard, Alroughani, Raed, Al-Asmi, A, Gerlach, O, Oh, J, Altintas, A, Tundia, N, Wong, SL, Butzkueven, H, Terzi, Murat, Hodgkinson, Suzanne, Laureys, Guy, Kalincik, Tomas, Van Der Walt, Anneke, Yamout, Bassem, Lechner-Scott, Jeannette. Sage Publications; 2023. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
Clarke, Laura, Bukhari, Wajih, McCombe, Pamela A., Sutton, Ian, Boggild, Mike, Brownlee, Wallace, Carroll, William M., Hodgkinson, Suzanne, Macdonell, Richard A.L., Mason, Deborah F., Pereira, Jennifer, Slee, Mark, O'Gorman, Cullen M., Das, Chandi, Henderson, APD, Kermode, AG, Lechner-Scott, Jeannette, Waters, P, Sun, J, Broadley, SA, Khalilidehkordi, Elham, Arnett, Simon, Woodhall, Mark, Prain, Kerri M., Parratt, John D.E., Barnett, Michael H., Marriott, Mark P.. Elsevier; 2022. Response to treatment in NMOSD: the Australasian experience.
Kalincik, Tomas, Jokubaitis, Vilja, Duquette, Pierre, Grammond, Pierre, Solaro, Claudio, Grand'Maison, Francois, Hupperts, Raymond, Prevost, Julie, Sola, Patrizia, Ferraro, Diana, Terzi, Murat, Butler, Ernest, Spelman, Tim, Slee, Mark, Kermode, Allan, Fabis-Pedrini, Marzena, McCombe, Pamela, Barnett, Michael, Shaw, Cameron, Hodgkinson, Suzanne, Butzkueven, Helmut, MSBase Study Group,, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Lechner-Scott, Jeannette, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc. Sage; 2018. Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis.
Kalincik, Tomas, Horakova, Dana, Spelman, Tim, Jokubaitis, Vilija, Trojano, Maria, Lugaresi, Alessandra, Izquierdo, Guillermo, Rozsa, Csilla, Grammond, Pierre, Alroughani, Raed, Duquette, Pierre, Girard, Marc, Pucci, Eugenio, Lechner-Scott, Jeannette, Slee, Mark, Fernandez-Bolanos, Ricardo, Grand'Maison, Francois, Hupperts, Raymond, Verheul, Freek, Hodgkinson, Suzanne. John Wiley & Sons; 2015. Switch to natalizumab versus fingolimod in active relapsing-remitting multiple sclerosis.
Zhong, Michael, van der Walt, Anneke, Macdonell, Richard, Prevost, Julie, Kuhle, Jens, Laureys, Guy, Van Hijfte, Liesbeth, Alroughani, Raed, Kermode, Allan G., Butler, Ernest, Barnett, Michael, Eichau, Sara, Stankovich, Jim, van Pesch, V, Grammond, P, McCombe, P, Karabudak, R, Duquette, P, Girard, M, Taylor, B, Yeh, W, Monif, M, Gresle, M, Kalincik, Tomas, Butzkueven, H, Jokubaitis, VG, Buzzard, Katherine, Skibina, Olga, Boz, Cavit, Hodgkinson, Suzanne, Slee, Mark, Lechner-Scott, Jeanette. Sage Publications; 2022. Prediction of multiple sclerosis outcomes when switching to ocrelizumab.
Kister, Ilya, Spelman, Tim, Grand'Maison, Francois, Alroughani, Raed, Terzi, Murat, Boz, Cavit, Hupperts, Raymond, Lechner-Scott, Jeannette, Kappos, Ludwig, Pucci, Eugenio, Hodgkinson, Suzanne, Solaro, Claudio, Patti, Francesco, Butzkueven, Helmut, Duquette, Pierre, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Grammond, Pierre, Sola, Patrizia, Ferraro, Diana. Elsevier; 2018. Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy.
Zhu, Chao, Kalincik, Tomas, Patti, Francesco, Grand'Maison, Francois, Hodgkinson, Suzanne, Grammond, Pierre, Lechner-Scott, Jeannette, Butler, Ernest, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Macdonell, Richard A. L., Horakova, Dana, Weinstock-Guttman, B, Ozakbas, S, Slee, M, Sa, MJ, Van Pesch, V, Barnett, M, Van Wijmeersch, B, Gerlach, O, Prevost, J, Terzi, M, Zhou, Zhen, Boz, C, Laureys, G, Van Hijfte, L, Kermode, AG, Garber, J, Yamout, B, Khoury, SJ, Merlo, D, Monif, M, Jokubaitis, V, Buzzard, Katherine, van der Walt, A, Butzkueven, H, MSBase, SG, Skibina, Olga, Alroughani, Raed, Izquierdo, Guillermo, Eichau, Sara, Kuhle, Jens. American Medical Association (AMA); 2023. Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
Malpas, Charles B., Roos, Izanne, Havrdova, Eva Kubala, Izquierdo, Guillermo, Eichau, Sara, Hodgkinson, Suzanne, Grammond, Pierre, Lechner-Scott, Jeannette, Kalincik, Tomas, MSBase Study Group,, Sharmin, Sifat, Buzzard, Katherine, Skibina, Olga, Butzkueven, Helmut, Kappos, Ludwig, Patti, Francesco, Alroughani, Raed, Horakova, Dana. Springer; 2022. Multiple Sclerosis Relapses Following Cessation of Fingolimod.
Zhu, Chao, Zhou, Zhen, Alroughani, Raed, Lechner-Scott, Jeannette, Barnett, Michael, Izquierdo, Guillermo, Prat, Alexandre, Horakova, Dana, Havrdova, Eva Kubala, Macdonell, Richard, Patti, Francesco, Khoury, Samia Joseph, Roos, Izanne, Slee, M, Karabudak, R, Onofrj, M, Van Pesch, V, Prevost, J, Monif, M, Jokubaitis, V, van der Walt, A, Butzkueven, H, Merlo, Daniel, Kalincik, Tomas, Ozakbas, Serkan, Skibina, Olga, Kuhle, Jens, Hodgkinson, Suzanne, Boz, Cavit. BMJ Group; 2022. Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.